Latest news newssearch boxGO 07 Feb 2019 Idorsia announces financial results for 2018 - outstanding progress made - four late stage assets advanced into Phase 3 05 Feb 2019 Idorsia announces the first patient recruited into REACT - the Phase 3 registration study with clazosentan 07 Jan 2019 Idorsia initiates a multiple-dose efficacy and safety study with cenerimod for the treatment of systemic lupus erythematosus 18 Dec 2018 Idorsia's P2Y12 receptor antagonist - selatogrel - Phase 2 clinical studies meet their objective 20 Nov 2018 Santhera enters into agreement to acquire option from Idorsia for exclusive sub-license of first-in-class dissociative steroid vamorolone 05 Nov 2018 Idorsia maintains collaboration agreement with ReveraGen 24 Oct 2018 Company statement 23 Oct 2018 Idorsia financial results for the first nine months of 2018 23 Oct 2018 Idorsia announces that Simon Jose is to join the company as Chief Commercial Officer 24 Jul 2018 Idorsia announces financial results for the first half 2018 11 Jul 2018 Idorsia successfully completes the offering of new shares and the offering of convertible bonds thereby securing long-term funding for the development of its advancing pipeline 10 Jul 2018 Idorsia launches the offering of new shares in combination with the offering of convertible bonds to fund the development of its advancing pipeline 20 Jun 2018 Idorsia initiates PRECISION - Phase 3 study with aprocitentan for resistant hypertension management 18 Jun 2018 Idorsia is initiating REACT - Phase 3 registration study with clazosentan 11 Jun 2018 Idorsia initiates a Phase 3 registration program with nemorexant (ACT-541468) for the treatment of insomnia 16 May 2018 Idorsia initiates MODIFY, a Phase 3 registration study to assess lucerastat as a potential new treatment option for patients with Fabry disease 24 Apr 2018 Idorsia holds its first Annual General Meeting of Shareholders - All Board proposals approved 19 Apr 2018 Idorsia announces financial results for the first quarter 2018 06 Feb 2018 Idorsia announces financial results for 2017 - company off to a great start - 4 compounds to enter Phase 3 development 20 Dec 2017 Idorsia forms research collaboration with Roche in the field of cancer immunotherapy 1 2
